Vivoryon Therapeutics 주식 주식분석 | 주식가격 | 뉴스 | VVY.AS | NL00150002Q7 | A2QJV6

날짜	Vivoryon Therapeutics 주식 가격
	2.24 undefined
	2.31 undefined
	2.34 undefined
	2.36 undefined
	2.39 undefined
	2.38 undefined
	2.47 undefined
	2.40 undefined
	2.42 undefined
	2.39 undefined
	2.36 undefined
	2.39 undefined
	2.36 undefined
	2.33 undefined
	2.38 undefined
	2.42 undefined
	2.36 undefined
	2.39 undefined
	2.45 undefined
	2.37 undefined
	2.33 undefined

날짜	Vivoryon Therapeutics 매출	Vivoryon Therapeutics EBIT	Vivoryon Therapeutics 이익
2030e	1.6 조. undefined	1.57 조. undefined	0 undefined
2029e	1.43 조. undefined	1.06 조. undefined	1.06 조. undefined
2028e	788.3 백만 undefined	763 백만 undefined	577.68 백만 undefined
2027e	0 undefined	151.8 백만 undefined	111.3 백만 undefined
2026e	0 undefined	-48.57 백만 undefined	-21.24 백만 undefined
2025e	0 undefined	-30.31 백만 undefined	-19.66 백만 undefined
2024e	0 undefined	-28.41 백만 undefined	-25.89 백만 undefined
2023	-3.62 백만 undefined	-28.84 백만 undefined	-28.34 백만 undefined
2022	0 undefined	-29.11 백만 undefined	-28.16 백만 undefined
2021	10.76 백만 undefined	-12.8 백만 undefined	-12.66 백만 undefined
2020	0 undefined	-16.01 백만 undefined	-16.51 백만 undefined
2019	0 undefined	-7.72 백만 undefined	-7.82 백만 undefined
2018	0 undefined	-7.7 백만 undefined	-7.74 백만 undefined
2017	0 undefined	-9.96 백만 undefined	-8.01 백만 undefined
2016	0 undefined	-13.78 백만 undefined	-13.89 백만 undefined
2015	0 undefined	-13.39 백만 undefined	-13.51 백만 undefined
2014	0 undefined	-11.27 백만 undefined	-11.44 백만 undefined
2013	0 undefined	-9.7 백만 undefined	-9.81 백만 undefined
2012	10,000 undefined	-10.59 백만 undefined	-18.72 백만 undefined
2011	20,000 undefined	-14.32 백만 undefined	-16.31 백만 undefined

	매출	EBIT	이익
2011	20,000 EUR	-14.32 백만 EUR	-16.31 백만 EUR
2012	10,000 EUR	-10.59 백만 EUR	-18.72 백만 EUR
2013	0 EUR	-9.7 백만 EUR	-9.81 백만 EUR
2014	0 EUR	-11.27 백만 EUR	-11.44 백만 EUR
2015	0 EUR	-13.39 백만 EUR	-13.51 백만 EUR
2016	0 EUR	-13.78 백만 EUR	-13.89 백만 EUR
2017	0 EUR	-9.96 백만 EUR	-8.01 백만 EUR
2018	0 EUR	-7.7 백만 EUR	-7.74 백만 EUR
2019	0 EUR	-7.72 백만 EUR	-7.82 백만 EUR
2020	0 EUR	-16.01 백만 EUR	-16.51 백만 EUR
2021	10.76 백만 EUR	-12.8 백만 EUR	-12.66 백만 EUR
2022	0 EUR	-29.11 백만 EUR	-28.16 백만 EUR
2023	-3.62 백만 EUR	-28.84 백만 EUR	-28.34 백만 EUR
2024e	0 EUR	-28.41 백만 EUR	-25.89 백만 EUR
2025e	0 EUR	-30.31 백만 EUR	-19.66 백만 EUR
2026e	0 EUR	-48.57 백만 EUR	-21.24 백만 EUR
2027e	0 EUR	151.8 백만 EUR	111.3 백만 EUR
2028e	788.3 백만 EUR	763 백만 EUR	577.68 백만 EUR
2029e	1.43 조. EUR	1.06 조. EUR	1.06 조. EUR
2030e	1.6 조. EUR	1.57 조. EUR	0 EUR

2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e	2030e
0	0	0	0	0	0	0	0	0	0	0.01	0	-0	0	0	0	0	0.79	1.43	1.6
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	81.47	11.54
-	-	-	-	-	-	-	-	-	-	90.00	-	100.00	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0	9	0	-3	0	0	0	0	0	0	0
-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.02	-0.01	-0.03	-0.03	-0.03	-0.03	-0.05	0.15	0.76	1.06	1.57
-	-	-	-	-	-	-	-	-	-	-120.00	-	933.33	-	-	-	-	96.83	74.34	98.50
-0.02	-0.02	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.02	-0.01	-0.03	-0.03	-0.03	-0.02	-0.02	0.11	0.58	1.06	0
-	12.50	-50.00	22.22	18.18	-	-38.46	-12.50	-	128.57	-25.00	133.33	-	-10.71	-24.00	10.53	-628.57	419.82	84.06	-
6.9	6.9	4.34	4.96	7.01	7.77	8.35	8.37	19.98	19.98	20	22.02	25.24	0	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

10.31	7.73	5.66	21.02	21.36	21.9	10.29	3.78	41.52	26.31	17.74	30.27	28.58
0	10	0	0	0	0	0	0	0	0	0	0	144
470	300	0	0	0	0	0	0	0	0	0	0	368
20	20	0	0	0	0	0	0	0	0	0	0	0
0.24	0.96	0.12	0.08	0.24	0.14	0.36	0.11	3.25	2.36	2.2	0.17	0.72
11.04	9.02	5.78	21.11	21.6	22.03	10.65	3.89	44.78	28.66	19.94	30.44	29.81
1.26	0.93	0.32	0.1	0.08	0.07	0.06	0.06	0.47	0.39	0.29	0.18	0.08
0	0	0	0	0	0	0	0	0	0	3.47	0.01	0
0	0	0	0	0	0	0	0	0	0.13	3.36	3.96	0
4.8	0.07	0.1	0.08	0.06	0.1	0.01	0.01	0.02	0.57	0.53	0.49	0.94
2	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	3.47	0.01	0
8.06	1	0.42	0.19	0.14	0.17	0.07	0.07	0.48	1.09	11.12	4.66	1.02
19.1	10.02	6.2	21.29	21.74	22.2	10.72	3.96	45.26	29.75	31.06	35.1	30.83

22.69	25.53	25.53	6.77	7.44	8.19	8.21	8.21	19.98	19.98	20.05	24.11	26.07
45.15	51.66	52.18	21.98	34.87	48.29	48.68	48.74	86.39	86.55	89.38	123.04	149.27
-52.87	-71.59	-81.81	-12.17	-25.68	-39.57	-47.58	-55.31	-63.14	-79.65	-92.3	-120.46	-148.8
-0.03	-0.23	-0.2	-0.6	-0.5	-0.53	-0.39	-0.41	-0.56	-0.66	-0.57	-0.18	-0.26
0	0	0	0	0	0	0	0	0	0	0	0	0
14.94	5.37	-4.3	15.97	16.13	16.38	8.92	1.23	42.67	26.22	16.56	26.51	26.28
1.22	0.73	1.31	1.04	1.63	1.89	0.34	0.77	0.54	0.91	4.36	2.54	2.89
1.77	2.73	2.58	2.72	2.96	3.09	0.25	0.08	0.24	0.18	0.23	0.25	0.24
160	110	80	820	323	158	75	110	62	147	366	381	11
0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	5.35	0	0	0	0	0	0.09	0.09	0.09	0.09	0.04
3.15	3.57	9.32	4.58	4.91	5.14	0.67	0.96	0.93	1.33	5.05	3.27	3.18
0	0	0	0	0	0	0	0	315	224	132	38	0
0	0	0	0	0	0	0	0	0	0	432	234	0
1.01	1.07	1.27	0.93	0.82	0.85	1.17	1.85	1.95	1.98	2.35	1.34	1.37
1.01	1.07	1.27	0.93	0.82	0.85	1.17	1.85	2.27	2.21	2.91	1.61	1.37
4.16	4.64	10.59	5.51	5.73	5.99	1.84	2.82	3.2	3.53	7.96	4.87	4.55
19.1	10.01	6.29	21.48	21.87	22.37	10.76	4.05	45.86	29.75	24.52	31.38	30.83

2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
-16	-18	-9	-11	-13	-13	-8	-7	-7	-16	-12	-28
0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0
1,000	0	0	0	0	0	-3,000	0	-3,000	1,000	0	0
0	6	0	1	1	0	0	0	0	0	1	6
0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	1,000	0	0	0	0	0
-14	-12	-8	-10	-12	-13	-12	-6	-11	-14	-11	-21
0	0	0	0	0	0	0	0	0	0	0	0
-1,000	1,000	0	1,000	0	0	0	0	0	0	0	0
0	1,000	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0
0	0	5	0	0	0	0	0	0	0	0	0
18	9	0	23	13	14	0	0	51	0	1	36
18	9	5	25	12	13	0	0	49	0	0	33
-	-	-	-	-	-	-	-	-1.00	-	-1.00	-2.00
0	0	0	0	0	0	0	0	0	0	0	0
3	-1	-3	16	0	0	-11	-6	37	-15	-11	11
-14.42	-12.16	-8.53	-10.6	-12.16	-13.38	-12.13	-7.01	-11.66	-14.08	-11.29	-21.81
0	0	0	0	0	0	0	0	0	0	0	0

Vivoryon Therapeutics 브루토마진	Vivoryon Therapeutics 이익 마진	Vivoryon Therapeutics EBIT-마진	Vivoryon Therapeutics 이익 마진
2030e	85.5 %	98.5 %	0 %
2029e	85.5 %	74.34 %	74.32 %
2028e	85.5 %	96.79 %	73.28 %
2027e	85.5 %	0 %	0 %
2026e	85.5 %	0 %	0 %
2025e	85.5 %	0 %	0 %
2024e	85.5 %	0 %	0 %
2023	85.5 %	796.6 %	782.93 %
2022	85.5 %	0 %	0 %
2021	85.42 %	-118.9 %	-117.57 %
2020	85.5 %	0 %	0 %
2019	85.5 %	0 %	0 %
2018	85.5 %	0 %	0 %
2017	85.5 %	0 %	0 %
2016	85.5 %	0 %	0 %
2015	85.5 %	0 %	0 %
2014	85.5 %	0 %	0 %
2013	85.5 %	0 %	0 %
2012	100 %	-105,900 %	-187,200 %
2011	100 %	-71,600 %	-81,550 %

	브루토마진	EBIT-마진	이익 마진
2011	100 %	-71,600 %	-81,550 %
2012	100 %	-105,900 %	-187,200 %
2013	85.5 %	0 %	0 %
2014	85.5 %	0 %	0 %
2015	85.5 %	0 %	0 %
2016	85.5 %	0 %	0 %
2017	85.5 %	0 %	0 %
2018	85.5 %	0 %	0 %
2019	85.5 %	0 %	0 %
2020	85.5 %	0 %	0 %
2021	85.42 %	-118.9 %	-117.57 %
2022	85.5 %	0 %	0 %
2023	85.5 %	796.6 %	782.93 %
2024e	85.5 %	0 %	0 %
2025e	85.5 %	0 %	0 %
2026e	85.5 %	0 %	0 %
2027e	85.5 %	0 %	0 %
2028e	85.5 %	96.79 %	73.28 %
2029e	85.5 %	74.34 %	74.32 %
2030e	85.5 %	98.5 %	0 %

날짜	Vivoryon Therapeutics 주당 매출	Vivoryon Therapeutics EBIT 당 주식	Vivoryon Therapeutics 주당 이익
2030e	61.19 undefined	0 undefined	0 undefined
2029e	54.86 undefined	0 undefined	40.77 undefined
2028e	30.24 undefined	0 undefined	22.16 undefined
2027e	0 undefined	0 undefined	4.27 undefined
2026e	0 undefined	0 undefined	-0.81 undefined
2025e	0 undefined	0 undefined	-0.75 undefined
2024e	0 undefined	0 undefined	-0.99 undefined
2023	-0.14 undefined	-1.14 undefined	-1.12 undefined
2022	0 undefined	-1.32 undefined	-1.28 undefined
2021	0.54 undefined	-0.64 undefined	-0.63 undefined
2020	0 undefined	-0.8 undefined	-0.83 undefined
2019	0 undefined	-0.39 undefined	-0.39 undefined
2018	0 undefined	-0.92 undefined	-0.92 undefined
2017	0 undefined	-1.19 undefined	-0.96 undefined
2016	0 undefined	-1.77 undefined	-1.79 undefined
2015	0 undefined	-1.91 undefined	-1.93 undefined
2014	0 undefined	-2.27 undefined	-2.31 undefined
2013	0 undefined	-2.24 undefined	-2.26 undefined
2012	0 undefined	-1.53 undefined	-2.71 undefined
2011	0 undefined	-2.08 undefined	-2.36 undefined

	주당 매출	EBIT 당 주식	주당 이익
2011	0 EUR	-2.08 EUR	-2.36 EUR
2012	0 EUR	-1.53 EUR	-2.71 EUR
2013	0 EUR	-2.24 EUR	-2.26 EUR
2014	0 EUR	-2.27 EUR	-2.31 EUR
2015	0 EUR	-1.91 EUR	-1.93 EUR
2016	0 EUR	-1.77 EUR	-1.79 EUR
2017	0 EUR	-1.19 EUR	-0.96 EUR
2018	0 EUR	-0.92 EUR	-0.92 EUR
2019	0 EUR	-0.39 EUR	-0.39 EUR
2020	0 EUR	-0.8 EUR	-0.83 EUR
2021	0.54 EUR	-0.64 EUR	-0.63 EUR
2022	0 EUR	-1.32 EUR	-1.28 EUR
2023	-0.14 EUR	-1.14 EUR	-1.12 EUR
2024e	0 EUR	0 EUR	-0.99 EUR
2025e	0 EUR	0 EUR	-0.75 EUR
2026e	0 EUR	0 EUR	-0.81 EUR
2027e	0 EUR	0 EUR	4.27 EUR
2028e	30.24 EUR	0 EUR	22.16 EUR
2029e	54.86 EUR	0 EUR	40.77 EUR
2030e	61.19 EUR	0 EUR	0 EUR

	주식 수량
2011	6.9 백만 Aktien
2012	6.9 백만 Aktien
2013	4.34 백만 Aktien
2014	4.96 백만 Aktien
2015	7.01 백만 Aktien
2016	7.77 백만 Aktien
2017	8.35 백만 Aktien
2018	8.37 백만 Aktien
2019	19.98 백만 Aktien
2020	19.98 백만 Aktien
2021	20 백만 Aktien
2022	22.02 백만 Aktien
2023	25.24 백만 Aktien
2024e	25.24 백만 Aktien
2025e	25.24 백만 Aktien
2026e	25.24 백만 Aktien
2027e	25.24 백만 Aktien
2028e	25.24 백만 Aktien
2029e	25.24 백만 Aktien
2030e	25.24 백만 Aktien

EPS-예상치	EPS-실제	보고 분기
-0.62	-0.52 (16.29 %)	2024 Q2
-0.58	-0.68 (-17.08 %)	2023 Q4
-0.61	-0.44 (27.39 %)	2023 Q2
-0.61	-0.68 (-12.21 %)	2022 Q4
-0.63	-0.6 (4.18 %)	2022 Q2
-0.41	-0.05 (87.93 %)	2021 Q4
-0.59	-0.58 (0.99 %)	2021 Q2
-0.42	-0.45 (-6.08 %)	2020 Q4
-0.16	-0.38 (-135.15 %)	2020 Q2
-0.39	-0.57 (-44.71 %)	2019 Q4
-0.25	-0.3 (-20.38 %)	2019 Q2
-0.39	-0.42 (-8.88 %)	2018 Q4
-0.72	-0.44 (38.97 %)	2017 Q4
-1.11	-0.99 (11.11 %)	2016 Q4
-1.06	-0.79 (25.05 %)	2016 Q2

%-지분	이름	주식	변경
10.07118 %	Christiansen (Claus)	2,625,235	-1,444,561
7.67086 %	Den Danske Forskningsfond	1,999,547	0
7.25546 %	T&W Holding A/S	1,891,267	-108,280
3.13617 %	Lupus alpha Asset Management AG	817,500	0
2.88195 %	Mackenzie Investments Europe Limited	751,232	-301,974
2.29859 %	UBS Asset Management (UK) Ltd.	599,168	409,293
1.94680 %	JPMorgan Asset Management U.K. Limited	507,469	-290,951
1.73592 %	Ethenea Independent Investors S.A.	452,500	0
1.29429 %	Matejka & Partner Asset Management GmbH	337,380	50,000
0.42199 %	amandea Verm¿gensverwaltung AG	110,000	0
0.20227 %	Mackenzie Investments Asia Limited	52,726	0
0.19181 %	UNIQA Towarzystwo Funduszy Inwestycyjnych S. A	50,000	0
0.13024 %	Weber (F)	33,950	0
0.08440 %	Azimut Capital Management Sgr SpA	22,000	0
0.05754 %	Quadriga Asset Managers SGIIC, S.A.	15,000	15,000
0.04834 %	Novum Asset Management AG	12,600	0
0.04795 %	GVC Gaesco Gesti¿n SGIIC S.A.	12,500	0
0.04604 %	FAM Frankfurt Asset Management AG	12,000	0
0 %	KIRIX Vermögensverwaltung AG	0	-10,000
0 %	ZEST SA	0	-15,000
0 %	Kieger AG	0	-31,300
0 %	Dimensional Fund Advisors, Ltd.	0	-1,596
0 %	GS&P Kapitalanlagegesellschaft S.A.	0	-1,330,000
0 %	Kohlberg Kravis Roberts & Co. L.P.	0	-2,054,796
0 %	Financi¿re Arbevel	0	-10,000
0 %	Hauck & Aufh¿user Fund Services S.A.	0	-10,000
0 %	Lemanik Invest SA	0	-323,658
0 %	Norges Bank Investment Management (NBIM)	0	-472,449
0 %	Schroder Investment Management Ltd. (SIM)	0	-28,323
0 %	Mackenzie Investments	0	-55,606
0 %	Dimensional Fund Advisors, L.P.	0	-5,400
0 %	Columbia Wanger Asset Management, LLC	0	-90,000
0 %	Schaeffer (Michael)	0	-3,867
0 %	Alphajet Fair Investors, SAS	0	-5,000
0 %	GSAM + Spee Asset Management AG	0	-6,500
0 %	Alpha Investor Services Management SA	0	-12,000

이름	관계	이주간 상관관계	원월 상관관계	삼개월 상관계수	여섯달 상관관계	일년간 상관관계	이년 상관관계
MorphoSys	공급업체고객	0,89	0,95	0,76	0,94	0,64	-0,60
IGM Financial	공급업체고객	0,58	0,80	0,71	0,79	0,48	0,79

What values and corporate philosophy does Vivoryon Therapeutics represent?

Vivoryon Therapeutics NV represents core values of innovation, collaboration, and commitment to addressing unmet medical needs. The company is dedicated to developing innovative small molecule therapeutics for challenging diseases, particularly in the field of age-related diseases. By fostering strong collaborations and partnerships, Vivoryon Therapeutics aims to accelerate the discovery and development of groundbreaking treatments. With a focus on precision medicine, the company seeks to improve patient outcomes and quality of life. Vivoryon Therapeutics NV is committed to advancing scientific knowledge and delivering effective therapies to patients worldwide.

In which countries and regions is Vivoryon Therapeutics primarily present?

Vivoryon Therapeutics NV is primarily present in Europe, specifically in Germany and the Netherlands.

What significant milestones has the company Vivoryon Therapeutics achieved?

Vivoryon Therapeutics NV has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in 2020, raising funds to further advance its innovative therapeutic programs. Vivoryon also received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead product candidate, QSI-001, a potential treatment for Alzheimer's disease. Moreover, Vivoryon has initiated multiple clinical trials, including Phase 1b/2a studies for QSI-001, demonstrating its commitment to advancing novel therapies for serious diseases. These milestones highlight Vivoryon Therapeutics NV's progress in developing transformative treatments and underline its dedication to improving patients' lives.

What is the history and background of the company Vivoryon Therapeutics?

Vivoryon Therapeutics NV is a biotech company that specializes in developing small molecule therapeutics for the treatment of neurodegenerative diseases. Founded in 2017, Vivoryon Therapeutics NV is based in Germany and focuses on targeting the ubiquitin-proteasome system and the unfolded protein response to tackle diseases like Alzheimer's and Parkinson's. The company's innovative platform has attracted numerous partnerships and collaborations with renowned academic institutions and pharmaceutical companies. With a strong commitment to research and development, Vivoryon Therapeutics NV aims to improve patients' lives by advancing novel therapies for neurodegenerative disorders.

Who are the main competitors of Vivoryon Therapeutics in the market?

The main competitors of Vivoryon Therapeutics NV in the market are other pharmaceutical and biotechnology companies that specialize in developing therapeutics for various diseases and conditions. These competitors include large multinational corporations as well as smaller research-focused organizations. It is important for Vivoryon Therapeutics NV to stay competitive in the market by continuously innovating and developing their drug candidates to address unmet medical needs.

In which industries is Vivoryon Therapeutics primarily active?

Vivoryon Therapeutics NV is primarily active in the healthcare and biotechnology industries.

What is the business model of Vivoryon Therapeutics?

The business model of Vivoryon Therapeutics NV is focused on developing small molecule drugs for treating age-related diseases. Vivoryon Therapeutics NV utilizes a unique approach called "drug surveillance technology" to identify specific enzymes involved in aging processes and develop novel drugs to target them. By targeting enzymes implicated in diseases like Alzheimer's and Parkinson's, Vivoryon Therapeutics NV aims to modify disease progression and improve patient outcomes. Through strategic partnerships, collaborations, and clinical trials, the company aims to bring innovative therapies to market and revolutionize the treatment landscape for age-related diseases.

Vivoryon Therapeutics 2024의 P/E 비율은 얼마입니까?

Vivoryon Therapeutics의 P/E 비율은 -2.18입니다.

Vivoryon Therapeutics 2024의 KUV는 얼마입니까?

Vivoryon Therapeutics의 P/S 비율은 0입니다.

Vivoryon Therapeutics의 AlleAktien 품질 점수는 얼마인가요?

Vivoryon Therapeutics에 대한 AlleAktien 품질 점수는 4/10입니다.

Vivoryon Therapeutics 2024의 매출은 얼마인가요?

Vivoryon Therapeutics에 대한 현재 매출은 계산할 수 없습니다.

Vivoryon Therapeutics 2024의 이익은 얼마인가요?

예상되는 Vivoryon Therapeutics 이익은 -25.89 백만 EUR입니다.

Vivoryon Therapeutics은 무엇을 하나요?

Vivoryon Therapeutics NV is a company specializing in the development of therapeutics for the treatment of age-related diseases. The company uses the latest technologies and research findings to discover and develop innovative compounds that can effectively combat age-related diseases. The business model of Vivoryon Therapeutics is based on the development and commercialization of drugs for the treatment of Alzheimer's disease, Parkinson's disease, ALS, and other age-related disorders. The company follows a rational drug discovery approach that focuses on the identification of molecules that specifically interact with disease processes. An important pillar of Vivoryon Therapeutics' business model is collaboration with partners and customers. The company works closely with pharmaceutical and biotech companies to license or sell its technologies and products. By collaborating with existing industry players, Vivoryon Therapeutics can leverage synergies and optimize the distribution of its products. Vivoryon Therapeutics has divided its business fields into several segments, each focused on the development of different products and technologies. The main segments include: 1. Discovery of drug candidates: The company uses its proprietary "Functional Tau Pipeline Technology" platform to discover and develop drug candidates that target disease processes specifically. 2. Drug development: Vivoryon Therapeutics employs innovative screening technologies and optimizes its drug candidates to enhance the efficacy and tolerability of the medications. The company also works on the development of combination therapies and personalized medicines. 3. Commercialization: The company aims to bring its products to the global market and become a leading provider of therapeutics for the treatment of age-related diseases worldwide. Vivoryon Therapeutics follows a strategy of direct sales but also collaborates with distribution partners to bring its products to various regional markets. The business model of Vivoryon Therapeutics is based on the development of innovative therapeutics for the treatment of age-related diseases, relying on the discovery and development of drug candidates and innovative screening technologies. The company works closely with other industry players to leverage synergies and optimize the distribution of its products. Vivoryon Therapeutics follows a strategy of direct sales but also collaborates with distribution partners to bring its products to various regional markets.

Vivoryon Therapeutics 배당금은 얼마입니까?

Vivoryon Therapeutics은(는) 연간 번의 배당을 통해 0 EUR의 배당금을 지급합니다.

Vivoryon Therapeutics이 얼마나 자주 배당을 지급하나요?

Vivoryon Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Vivoryon Therapeutics ISIN이 무엇입니까?

Vivoryon Therapeutics의 ISIN은 NL00150002Q7입니다.

Vivoryon Therapeutics WKN은 무엇인가요?

Vivoryon Therapeutics의 WKN은 A2QJV6입니다.

Vivoryon Therapeutics 티커는 무엇인가요?

Vivoryon Therapeutics의 티커는 VVY.AS입니다.

Vivoryon Therapeutics이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Vivoryon Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Vivoryon Therapeutics은(는) 0 EUR의 배당금을 지급할 것으로 예상됩니다.

Vivoryon Therapeutics의 배당 수익률은 얼마입니까?

Vivoryon Therapeutics의 현재 배당 수익률은 입니다.

Vivoryon Therapeutics의 배당금은 언제 지급되나요?

Vivoryon Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Vivoryon Therapeutics의 배당금은 얼마나 안전한가요?

Vivoryon Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Vivoryon Therapeutics의 배당금은 얼마입니까?

향후 12개월 동안 0 EUR의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Vivoryon Therapeutics이(가) 속해 있는 섹터는 어디인가요?

Vivoryon Therapeutics은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Vivoryon Therapeutics kaufen, um die vorherige Dividende zu erhalten?

Vivoryon Therapeutics의 마지막 배당금을 0 EUR만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Vivoryon Therapeutics의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Vivoryon Therapeutics의 2023년도 배당금은 얼마였습니까?

2023년에 Vivoryon Therapeutics는 0 EUR를 배당금으로 지급했습니다.

Vivoryon Therapeutics는 어떤 화폐로 배당금을 지급하나요?

Vivoryon Therapeutics의 배당금은 EUR에 지급됩니다.

증권거래소	Vivoryon Therapeutics 티커
암스테르담	VVY.AS
뒤셀도르프	05Y.DU
EURONEXT	VVY.AS
프랑크푸르트	05Y.F
LONDON	0R3M.L
LONDON STOCK EXCHANGE	0R3M.L
뮌헨	05Y.MU

Vivoryon Therapeutics 티커	Vivoryon Therapeutics FIGI
VVY:NA	BBG0079ZD8K3
05Y:GR	BBG007BB73G6
05Y:GF	BBG007BB73H5
05Y:GD	BBG007BB73K1
05Y:GS	BBG007BB73N8
05Y:GM	BBG007BB73P6
05Y:GB	BBG007BB73Q5
PBDEUR:XH	BBG007BQJ0Y6
PBDEUR:XF	BBG007BQJ101
PBDEUR:XE	BBG007BQJ129
PBDEUR:XL	BBG007BQJ147
PBDEUR:XG	BBG007BQJ156
PBDEUR:XO	BBG007BQJ165
PBDEUR:XA	BBG007BQJ1C8
PBDEUR:XT	BBG007BQJ1F5
PBDEUR:XW	BBG007BQJ1G4
PBDEUR:XU	BBG007BQJ1H3
PBDEUR:XV	BBG007BQJ1K9
PBDEUR:EU	BBG007BQJ1P4
VVYA:IX	BBG007F8W8V3
VVYA:EB	BBG007F8WBL7
VVYA:S1	BBG007FMGJG3
VVYA:B3	BBG007WWWZF9
VVYA:L3	BBG007WX08B6
VVYA:PO	BBG008H094S5
05Y:TH	BBG00BTF5NY7
VVYA:TQ	BBG00H9NJTV4
PBDEUR:XM	BBG00J9WH1L4
0R3M:LN	BBG00JHW6J47
PBDGBX:XH	BBG00KXKCXH0
PBDGBX:XF	BBG00KXKCXK6
PBDGBX:XE	BBG00KXKCXM4
PBDGBX:XL	BBG00KXKCXP1
PBDGBX:XG	BBG00KXKCXQ0
PBDGBX:XO	BBG00KXKCXR9
PBDGBX:XA	BBG00KXKCXW3
PBDGBX:XT	BBG00KXKCXY1
PBDGBX:XW	BBG00KXKCXZ0
PBDGBX:XU	BBG00KXKCY06
PBDGBX:XV	BBG00KXKCY15
PBDGBX:XM	BBG00KXKCY24
PBDGBX:EU	BBG00KXKCY88
VVYA:T1	BBG00NLK2S89
VVYA:I2	BBG00Q5FQ139
PBDEUR:X2	BBG00Q6RYCL9
05Y:QT	BBG00RLSCF08
05Y:GZ	BBG00Y2FZJJ9
VVYA:L1	BBG00Y941Z17
VVYA:S4	BBG00YJ7WVH7
VVYA:QX	BBG016DSD9Q7
VVYA:QE	BBG016DV7VY9
VVYA:BQ	BBG016RSSTD6
05Y:LA	BBG018H9CFL3
05Y:LU	BBG018J30GC5

한 눈에 저평가된 주식을 인식하세요

가격

가격

티커VVY.AS

ISINNL00150002Q7

WKNA2QJV6

Vivoryon Therapeutics 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Vivoryon Therapeutics 주가 이력

Vivoryon Therapeutics 주식 매출, EBIT, 이익 NL00150002Q7 · A2QJV6

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Vivoryon Therapeutics 매출, 이익 및 EBIT 역사

Vivoryon Therapeutics 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Vivoryon Therapeutics 주식 마진 NL00150002Q7 · A2QJV6

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Vivoryon Therapeutics 마진 역사

Vivoryon Therapeutics 주식 매출, EBIT, 주당 순이익 NL00150002Q7 · A2QJV6

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Vivoryon Therapeutics 매출, 이익 및 EBIT 주당 역사

Vivoryon Therapeutics 주식 및 주식 분석

Vivoryon Therapeutics Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Vivoryon Therapeutics 역사적인 P/E, EBIT 및 P/S에 따른 평가

Vivoryon Therapeutics 주식 수량 NL00150002Q7 · A2QJV6

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

한눈에 과소평가된 주식을 인식하세요.

Vivoryon Therapeutics 수익 예상

Vivoryon Therapeutics 수익 놀라움

Vivoryon Therapeutics 주식 주주 구조

Vivoryon Therapeutics 임원진 및 경영진

Vivoryon Therapeutics 공급망

Vivoryon Therapeutics 주식에 대한 자주 묻는 질문

What values and corporate philosophy does Vivoryon Therapeutics represent?

In which countries and regions is Vivoryon Therapeutics primarily present?

What significant milestones has the company Vivoryon Therapeutics achieved?

What is the history and background of the company Vivoryon Therapeutics?

Who are the main competitors of Vivoryon Therapeutics in the market?

In which industries is Vivoryon Therapeutics primarily active?

티커
VVY.AS

ISIN
NL00150002Q7

WKN
A2QJV6